Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ALT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH NCT07795164 · Metabolic Dysfunction-Associated Steatohepatitis (MASH) Pemvidutide, Placebo | ALT Altimmune, Inc. | Phase 3 | Recruiting | 1,800 | Dec 2028 | Registry ↗ |
| Aug 17, 2026 | RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associat… NCT07009860 · Alcohol-associated Liver Disease Pemvidutide, Placebo | ALT Altimmune, Inc. | Phase 2 | Active, not recruiting | 121 | Sep 30, 2027 | Registry ↗ |
| Jul 31, 2026 | RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol… NCT06987513 · Alcohol Use Disorder (AUD) Pemvidutide, Placebo | ALT Altimmune, Inc. | Phase 2 | Completed | 100 | Jul 30, 2026 | Registry ↗ |
| May 18, 2026 | IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NAS… NCT05989711 · Non-Alcoholic Steatohepatitis (NASH) Pemvidutide, Placebo | ALT Altimmune, Inc. | Phase 2 | Completed | 212 | Nov 25, 2025 | Registry ↗ |
| Dec 8, 2025 | HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) NCT04684914 · Hepatitis B, Chronic HepTcell, Placebo | ALT Altimmune, Inc. | Phase 2 | Terminated | 87 | Mar 27, 2024 | Registry ↗ |
| Jun 24, 2025 | ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) NCT05134662 · Type 2 Diabetes ALT-801, Placebo | ALT Altimmune, Inc. | Phase 1 | Completed | 55 | Feb 3, 2023 | Registry ↗ |
| Jun 24, 2025 | Pemvidutide (ALT-801) DDI Study in Healthy Volunteers NCT04972396 · NASH - Nonalcoholic Steatohepatitis Pemvidutide, Metformin | ALT Altimmune, Inc. | Phase 1 | Completed | 40 | May 15, 2022 | Registry ↗ |
| Jun 24, 2025 | ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability NCT04561245 · Obesity, Nonalcoholic Steatohepatitis ALT-801, Placebo | ALT Altimmune, Inc. | Phase 1 | Completed | 100 | Oct 29, 2021 | Registry ↗ |
| Jun 24, 2025 | NasoShield in Healthy Adults to Study Safety and Immunogenicity NCT04415749 · Healthy Volunteers NasoShield, Placebo | ALT Altimmune, Inc. | Phase 1 | Completed | 43 | Mar 15, 2021 | Registry ↗ |
| Jun 24, 2025 | NasoShield Study of Safety and Immunogenicity NCT03352466 · Healthy Volunteers NasoShield, BioThrax | ALT Altimmune, Inc. | Phase 1 | Completed | 145 | May 13, 2019 | Registry ↗ |
| Jun 19, 2025 | Study of the Safety and Immunogenicity of NasoVAX Extension NCT03760549 · Influenza Subjects were administered NasoVAX high dose | ALT Altimmune, Inc. | — | Completed | 8 | Feb 18, 2019 | Registry ↗ |
| May 29, 2025 | Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. NCT00755703 · Influenza A Subtype H5N1 Infection Pandemic Influenza Vaccine, Placebo | ALT Altimmune, Inc. | Phase 1 | Completed | 48 | Sep 2009 | Registry ↗ |
| May 22, 2025 | Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B NCT02496897 · Hepatitis B FP-02.2 Vaccine, Placebo | ALT Altimmune, Inc. | Phase 1 | Completed | 61 | Oct 13, 2017 | Registry ↗ |
| Apr 30, 2024 | Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX NCT03232567 · Influenza NasoVAX | ALT Altimmune, Inc. | Phase 2 | Completed | 60 | Mar 7, 2018 | Registry ↗ |
| Nov 29, 2023 | Efficacy and Safety of ALT-801 in the Treatment of Obesity NCT05295875 · Obesity/Overweight ALT-801, Placebo | ALT Altimmune, Inc. | Phase 2 | Completed | 391 | Sep 28, 2023 | Registry ↗ |
| Aug 14, 2023 | Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) NCT04679909 · Healthy Volunteers AdCOVID, Placebo | ALT Altimmune, Inc. | Phase 1 | Completed | 92 | Dec 1, 2021 | Registry ↗ |
| Jul 27, 2023 | Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) NCT05292911 · Non-Alcoholic Fatty Liver Disease ALT-801, Placebo | ALT Altimmune, Inc. | Phase 1 | Completed | 64 | Oct 31, 2022 | Registry ↗ |
| Jul 27, 2023 | ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver D… NCT05006885 · Non-Alcoholic Fatty Liver Disease ALT-801, Placebo | ALT Altimmune, Inc. | Phase 1 | Completed | 95 | Aug 17, 2022 | Registry ↗ |
| Apr 4, 2022 | NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) NCT04442230 · Coronavirus Infection NasoVAX, Placebo | ALT Altimmune, Inc. | Phase 2 | Terminated | 48 | Feb 15, 2021 | Registry ↗ |
| Apr 26, 2019 | Immune Response Following Seasonal Influenza Vaccination NCT03163342 · Influenza Licensed seasonal influenza vaccine | ALT Altimmune, Inc. | Phase 4 | Completed | 20 | Nov 21, 2017 | Registry ↗ |
20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances